NATALEE: Phase III study of ribociclib (RIBO) plus endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC).

被引：43

作者：

Slamon, Dennis J.

Fasching, Peter A.

Patel, Ravindranath

Verma, Sunil

Hurvitz, Sara A.

Chia, Stephen K. L.

Crown, John

Martin, Miguel

Barrios, Carlos H.

Spera, Gonzalo

Lopez, Celine

Hor, Ines

Pelov, Diana

Hughes, Gareth

Nawinne, Moditha

Hortobagyi, Gabriel N.

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[2] Univ Hosp Erlangen, Erlangen, Germany

[3] Comprehens Blood & Canc Ctr, Bakersfield, CA USA

[4] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada

[5] BC Canc Agcy, Vancouver, BC, Canada

[6] St Vincents Univ Hosp, Dept Med Oncol, Dublin, Ireland

[7] Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain

[8] Latin Amer Cooperat Oncol Grp, Porto Alegre, RS, Brazil

[9] Translat Res Oncol, Montevideo, Uruguay

[10] Translat Res Oncol TRIO, Paris, France

[11] Novartis Pharmaceut, E Hanover, NJ USA

[12] Novartis Pharma AG, Basel, Switzerland

[13] Novartis Pharma AG, Basil, Switzerland

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.TPS597

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS597

引用

页数：2

共 50 条

[21] First-line ribociclib plus letrozole in postmenopausal Asian women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2
Yap, Y. S.
Tseng, L-M.
Blackwell, K. L.
Cameron, D.
Foo, S.
Sriuranpong, V.
Huang, C-S.
Chao, T-Y.
Kim, T-Y.
Chen, S-C.
Jung, K. H.
Lee, K. S.
Sohn, J-H.
Kim, J. H.
Hou, M-F.
Han, Y.
Souami, F.
Dhuria, S.
Miller, M.
Verma, S.
ANNALS OF ONCOLOGY, 2016, 27
[22] Efficacy and safety of palbociclib plus fulvestrant in Asian women with hormone receptor-positive (HR plus )/human epidermal growth factor-2 negative (HER2-) metastatic breast cancer (MBC) that progressed on prior endocrine therapy (ET)
Ro, J.
Im, S-A.
Masuda, N.
Im, Y-H.
Inoue, K.
Rai, Y.
Nakamura, R.
Kim, J. H.
Zhang, K.
Giorgetti, C.
Schnell, P.
Bartlett, C. Huang
Iwata, H.
ANNALS OF ONCOLOGY, 2015, 26 : 16 - 16
[23] Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR plus ) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review
Zhu, Linhui
Wang, Mengmeng
Luo, Xin
Li, Huan
Shan, Han
Du, Qiong
Zhai, Qing
ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (04)
[24] The Prognostic Impact of Adjuvant Endocrine Therapy by Age for Patients with Small Estrogen Receptor-Positive (ER plus ), Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer
Takahashi, Yuko
Sasada, Shinsuke
Kondo, Naoto
Hashimoto, Hiroya
Terata, Kaori
Kida, Kumiko
Sagara, Yasuaki
Naito, Yoichi
Anan, Keisei
Ueno, Takayuki
Suto, Akihiko
Kanbayashi, Chizuko
Takahashi, Mina
Nakamura, Rikiya
Ishiba, Toshiyuki
Tsuneizumi, Michiko
Nishimura, Seiichiro
Ozaki, Yukinori
Shimomura, Akihiko
Sakai, Takehiko
Iwatani, Tsuguo
Shigematsu, Hideo
CANCER RESEARCH, 2024, 84 (09)
[25] Ribociclib (RIBO) plus letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial
Abdel-Razeq, H.
Cottu, P. H.
Ring, A.
De laurentiis, M.
Lu, J.
Azim, H. A.
Zamagni, C.
Zhou, K.
Wu, J.
Menon, L.
Martin, M.
ANNALS OF ONCOLOGY, 2018, 29
[26] Ribociclib (RIBO) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial
Zamagni, C.
Campone, M.
Kudryavcev, I.
Brown-Glaberman, U.
Cottu, P. H.
Ring, A.
Lu, J.
Martin, M.
De laurentiis, M.
Zhou, K.
Wu, J.
Menon, L.
Azim, H. A.
ANNALS OF ONCOLOGY, 2018, 29
[27] Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Cobain, Erin F.
Hayes, Daniel F.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (32) : 3673 - +
[28] Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer: A Systematic Literature Review
Carter, Gebra Cuyun
Mohanty, Maitreyee
Stenger, Keri
Guimaraes, Claudia Morato
Singuru, Shivaprasad
Basa, Pradeep
Singh, Sheena
Tongbram, Vanita
Kuemmel, Sherko
Guarneri, Valentina
Tolaney, Sara M.
CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 6537 - 6566
[29] Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (aBC) with no prior endocrine therapy (ET) for ABC: CompLEEment-1 trial, preliminary results from Spanish population
Salvador, J.
Ciruelos, E. M.
Prat, A.
Jimenez-Rodriguez, B.
de la Cruz, L.
Martinez, N.
Villanueva Vazquez, R.
de Toro, R.
Anton, A.
Moreno, F.
Alvarez, I.
Gavila, J.
Quiroga, V.
Vicente, E.
de la Haba, J.
Gonzalez-Santiago, S.
Diaz, N.
Barnadas, A.
Cantos Sanchez de Ibarguen, B.
Delgado, J. I.
Bellet, M.
Gimeno, A.
Sanz, S.
Martin, M.
CANCER RESEARCH, 2019, 79 (04)
[30] Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial
Lu, Janice
Cottu, Paul
Martin, Miguel
Zamagni, Claudio
Prat, Aleix
Chia, Stephen
Jerusalem, Guy
Rajappa, Senthil
Timcheva, Constanta
Zhukova, Lyudmila
Zhou, Katie
Wu, Jiwen
Menon-Singh, Lakshmi
De Laurentiis, Michelino
CANCER RESEARCH, 2021, 81 (04)

← 1 2 3 4 5 →